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A -Excretion fractions used for urinary, fecal and biliary excretion. Cummings et al. (1967) , Forrest et al. (1982) , Lauterburg et al. (1980) For at home excretion of persistent pharmaceuticals, the pharmacokinetic characteristics for the selected compounds were considered and retrieved from www.farmacotherapeutischkompas.nl. Our hypothetic patient is an average Dutch with a bodyweight of 78kg (according to CBS) with a corresponding body surface area of 1.94m2. Plasma concentrations were modelled according to equations (1) and (2) which use as input the terms described by equations (3) -(6).
For multiple oral intake:
(1)
For multiple intravenous intake:
(2) = 0 * � 1− − * * 1− − * � * − * Where:
(3) 0 = * (4) The at-home-excretion factor was calculated according to equations (7) and (8):
(area under the curve)
The area-under-the-curve method was applied for azithromycin, ciprofloxacin, sulfamethoxazole, trimethoprim, fluoxetine, ifosfamide, naproxen and carbamazepine since these pharmaceuticals are commonly administered for several days. Due to their pharmacokinetic properties (high absorption constant but low elimination constant), these compounds accumulate progressively in the body during the treatment resulting in elevated and stable plasma concentrations (see Fig. 1 A) . After termination of the treatment, plasma concentrations decline only slowly resulting in continuous compound excretion even days after the last dose was consumed.
Contrast media (iopromide, iomeprole) are usually administered intravenously and as single dose to facilitate imaging procedures. Maximum plasma concentrations are reached quickly after administration and decline exponentially. If patients leave for instance 45 minutes after administration the hospital, the fraction of the administered dose which is likely to be excreted outside the hospital can be determined by the ratio the plasma concentrations at the time leaving the hospital in relation to the maximum plasma concentration. To determine the at-home excretion factor of cytarabine, a combination of plasma concentration and dosing ratio was assumed which is described in detail below.
B.3 -Assumptions on dosing routines.

Antibiotics
Since all selected antibiotics are usually prescribed for rather uncomplicated diseases such as bladder infections, bronchitis, middle ear infection (otitis), nasal sinusitis and similar, which do not require long hospitalization, it is assumed that patients who got antibiotics prescribed for oral intake, leave the hospital after 3 days. For IV administered antibiotics, it is assumed that all excretion occurs within the hospital.
Azithromycin is commonly administered for oral intake as a single dose of 500mg per day for 3 days and for uncomplicated infections. Thus it is assumed that patients stay for only 3 days hospitalized when azithromycin is prescribed orally.
Ciprofloxacin is commonly prescribed when patients suffer from rather uncomplicated infections like bladder infections, bronchitis, middle ear infection (otitis), nasal sinusitis and similar. Usually, none of these diseases require hospitalization. Dosing routine is assumed to entail 500mg every 12 hours for 7 days. Patients are expected to leave the hospital after 3 days and to finish the dose at home.
Sulfamethoxazole is usually administered as combi-preparation with trimethoprim at a ratio of 83,3% S : 16,7% T (Co-trimoxazol) for both oral and IV intake. The purchase data of both hospitals and the consumption data of non-patients were corrected accordingly. The share of trimethoprim in Cotimoxazol was added to the purchase data of single Trimethoprim. Common dosing routines entail 960mg every 12 hours for 7 days. Orally prescribed co-trimoxazol tackles mostly infections of the urinary tract, the respiratory system or similar which do not require hospitalization. Consequently, it was assumed that these patients leave the hospital after 3 days. Patients who get intravenously administered Co-trimoxazol are expected to stay hospitalized for the average duration of hospitalization of the respective hospital (Radboudumc: 5.4 days, Utrecht UMC: 6.7 days).
Cytostatica
Ifosfamide is assumed to be only administered at the nursing departments of the hospitals, thus no athome excretion is assumed to take place.
For cytarabine, a hypothetic treatment was designed according to College der Beoordeling van Geneesmiddelen. Cytarabine treatment follows commonly three main stages: start of the treatment (induction), intermediate treatment and maintenance treatment.
During induction phase, a doses of 2 mg/kg and day is administered once per day for the duration of 10 consecutive days. For an average Dutch person this results in a total administration of 1,56 g cytarabine during the induction phase. After promising results have been obtained, the treatment continues in the next phase.
During this intermediate phase, 3 -5 mg/ kg and day are administered for 5 consecutive days, followed by a recovery period of 5 days. This cycle is repeated at least 3 times after which (given positive results), the treatment continues to the maintenance stage. Assuming 3 cycles of the maximum dose of 5 mg/kg and day, a patient receives during this stage in total 5,85 g cytarabine.
The maintenance stage is here assumed to continue for 10 weeks of 2 weekly doses of 1 mg/kg each, resulting in a total of 1,56 g cytarabine. At the end of this treatment, a patient was administered thus a total of 8,97 g of cytarabine.
It was then assumed that the patient is hospitalized for the entire duration of the induction stage. Due to its fast clearance from the body, the entire cumulative dose is assumed to be excreted in the hospital. For the intermediate and the maintenance stage, the patient is not hospitalized. It is assumed that the patient comes to the hospital for each of the injections of cytarabine (which takes about 30 min) and leaves the hospital 1,5 h after. When leaving after 1,5 hours the hospital, the 59,4% of each dose is expected to be excreted outside the hospital. For the entire treatment (inductionintermediate -maintenance), this would result in an at-home excretion of 4,4 g cytarabine equal to 49% of the total administration (4,4/8,97=0,49).
Contrast media
For iopromide the recommended dose is 4ml ultravist-300/kg bodyweight. The purchased contrast medium Ultravist-300 contains 623mg iopromide/mL 10 , the total dose for a 78kg person is thus 194g.
Patients are expected to leave hospital after 45 min.
Similarly, iomeprol is assumed to be administered as an intravenous average dose of 100mL iomeron-250 which contains 510mg iomeprol/mL 11 . Patients are assumed to leave the hospital after 45 min.
Others
Fluoxetine is assumed to be administered as 20 mg every 24 hours. Patients are assumed to stay for the average time of hospitalization. (Radboudumc: 5.4 days, Utrecht UMC: 6.7 days).
Carbamazepine is assumed to be administered as 400mg every 12 hours for 7 days. Patients are assumed to stay for the average time of hospitalization. (Radboudumc: 5.4 days, Utrecht UMC: 6.7 days).
Naproxen is assumed to be administered as starting dose 3x 250mg on thirst day, followed by a maintenance dose of 2x 500mg per day for 7 days.Patients are assumed to stay for the average time of hospitalization. (Radboudumc: 5.4 days, Utrecht UMC: 6.7 days).
B.4 -At-home excretion: Calculations and results.
See Excel SI (1).
C -Non-patient emission calculations
See Excel SI (2). Straub (2016) . 13 PNEC used as described in Straub (2013) . 14 PNEC used as described in Steger-Hartmann et al. (1999) . The ecotoxicological data used to derive the PNECs presented in Table 3 can be found in SI (3). Salt forms of the compounds ciprofloxacin, diclofenac, ibuprofen, naproxen, metformin and metoprolol are included in the toxicity tables, because when these enter the aquatic environment they turn into their base forms (Tischler et al., 2011) .
D -Predicted no-effect concentrations (PNECs) used.
Azithromycin
One toxicity value of D. magna is not taken into account for the derivation of the PNEC.
The reason for this was that there was no endpoint and exposure time available for this particular value. Besides, the same concentration was noted by the same source with an identical exposure time and endpoint. Excluding this toxicity value did not have any influence on the PNEC, since there was no other data available for D. magna. For the derivation of the PNEC, five EC50 were available of five different species. The most sensitive species based on the acute toxicity data appeared to be the cyanobacteria, (EC50 = 9.4*10 -4 mg/L), which is not surprising since azithromycin is an antibiotic which is designed to attack bacteria (Treyaprasert et al., 2007) . No chronic data available for a cyanobacteria species and the lowest NOEC value was 4.4*10 -3 mg/L for the crustacean C. dubia. Based on the available data, an assessment factor of 50 was used, resulting in a PNEC of 8.8*10 -5 mg/L. This is in contrast with ECHA (2008, chapter R.10 p. 19), which states that when the lowest NOEC value is higher than the lowest EC50 value an assessment factor of 100 needs to be used on the NOEC (instead of 50). However, based on the ratio between the acute and chronic toxicity data of P. subcapitata a rough estimation can be made for the NOEC of cyanobacteria (2.57*10 -4 mg/L). This estimated NOEC is still higher than the derived PNEC, and therefore expected to be conservative enough.
Ciprofloxacin
The reason for the exclusion of some toxicity data for the PNEC derivation was because of the non-population relevant endpoints (e.g. enzyme activity and physiology changes).
There were acute toxicity values (EC50) for nine different species and for 6 species there were chronic NOECs or EC10s available. No useful acute and chronic data was available for a fish species, and therefore an assessment factor of 50 was used for the derivation of the PNEC. The most sensitive species based on the chronic data was for this antibiotic A. flosaquae, a cyanobacteria species. Ciprofloxacin belongs to the class of fluoroquinolone antibiotics, which are broadly used as a medicine for humans but also for veterinary purposes. Ciprofloxacin inhibits the activity of bacterial DNA gyrase, an enzyme that is needed for DNA replication and transcription (Ebert et al., 2011) . Due to this mode of action it is not surprising that a bacteria species is the most sensitive species. The PNEC was derived with the assessment factor of 50 and applied to the NOEC of A. flos-aquae.
With the nine acute toxicity values, the species sensitivity distribution method was used to determine the hazardous concentration at which 5% (HC5) of the species is affected for 50%. This HC5 was divided by 10 because it is based on acute toxicity data.
Cytarabine
Only acute toxicity data was available for three taxonomic groups, but there was no L(E)C50 present for fish. According to van Herwijnen et al. (2009) an assessment factor of 3000 needs to be applied to safeguard that the PNEC value is low enough. With this assessment factor, a PNEC of 5.67*10 -3 mg/L was derived.
Ifosfamide
The only relevant data for the derivation of the PNEC for ifosfamide were based on fish studies. Toxicity data from Baxter Safety Data Sheet were not included, because no endpoint was reported. Both L(E)C50 values were based on the species D. rerio. Due to this little acute data an assessment factor of 10000 was applied (Herwijnen et al., 2009) . This led to a PNEC of 8.09*10 -1 mg/L.
Iomeprol
No toxicity tests were available for the contrast media iomeprol. However, there were QSAR values available for this compound (SI (3) ). Mendoza et al. (2015) used an assessment factor of 1000 to derive the PNEC, however this is too low since an assessment factor of 1000 is also used for the same amount of data with toxicity studies. Therefore an higher assessment factor, 5000, is used in this study to derive the PNEC, which is 1.76*10 -1 mg/L (Herwijnen et al., 2009) .
Diclofenac
For diclofenac two PNEC values were calculated, because there is some debate about the endpoints that are tested in toxicity studies with diclofenac, in particular their population relevence (Moermond & Smit, 2015) . Wolf et al. (2014) reviewed four different studies that were done on the effects on the liver, kidney and gills. It is said that contrasting outcomes between these studies were due to different diagnostic interpretation. In this study the two last values of the table in SI (3) were derived by testing the fishes on histopathological changes in the liver, kidney and gills. These two values were from three studies that were described in Wolf et al. (2014) , namely Hoeger et al. (2005) , Schwaiger et al. (2004) and Mehinto et al. (2010) . The two latter had the same concentration at which no effect was observed. Initially, the data from the three abovementioned studies were not included for the first derivation of the PNEC. This resulted in a PNEC of 1*10 -1 mg/L using an assessment factor of 10. When the reviewed toxicity data were included in the derivations, the PNEC value appeared to be much lower 5.00*10 -5 mg/L. This second derivation of the PNEC is called diclofenac2 in Table 4 and 5. For this study we chose to use the more conservative PNEC of 5.00*10 -5 mg/L.
Ibuprofen
Toxicity values that are excluded for the derivation of the PNEC did not have population relevant endpoints (concentration in gills of P. notatus and DNA-damage to D. rerio). There was one NOEC for D. magna that had a lower than sign (<), which meant that the NOEC was lower than the given value. To correct for this, the concentration was divided by two, resulting in a NOEC of 0.615 mg/L for the reproduction of D. magna. There was another NOEC available for the same species and same endpoint with a concentration of 20 mg/L.
Since this value is much higher than 0.615 it was considered reliable to derive the NOEC with the geometric mean of 20 and 0.615 for the reproduction of D. magna. Enough chronic toxicity data was available to use an assessment factor of 10 resulting in a PNEC of 1*10 -4 mg/L for ibuprofen.
Naproxen
Acute toxicity data was available for ten different species belonging to seven different taxonomic groups. Only five chronic NOECs and EC10s were available for the PNEC derivation belonging to four taxonomic groups. However, no NOEC was present for a fish species, and therefore an assessment factor of 50 was used for the PNEC derivation. The calculated PNEC is 1.70*10 -3 mg/L.
Paracetamol
Toxicity data with non-population relevant endpoints were not included for the PNEC derivation. The PNEC of 1.90*10 -2 mg/L was derived using an assessment factor of 50 because there was no chronic data available of an algae species.
Carbamazepine
Toxicity data that was not used for the PNEC derivation had no population relevant endpoints or were not reported at all. The latter was the case for the NOEC found in the study of Weight et al. (2011) . Excluding this chronic NOEC (7.88*10 -3 mg/L) may have influence on the PNEC because of its low value. The exclusion of the NOEC (≥ 0.1 mg/L) from the study of Schwaiger et al. (2004) has an effect on the PNEC as well. The reason for this exclusion is the same as the exclusion of some toxicity data for the PNEC derivation of diclofenac. In contrast to diclofenac, for carbamazepine no second PNEC is derived with this data, due to the unreliability the study of Schwaiger et al., (2004) described by Moermond & Smit (2015) . To obtain a NOEC for P. subcapitata, the geometric mean is calculated with a 0.521 mg/L and 100 mg/L. However, the latter had a greater than sign (>) but due to the large difference between the two it is assumed that the NOEC would not be much higher than 100. Enough chronic data was available for the basic set of species, and therefore an assessment factor of 10 was used to derive the PNEC resulting in a 2.5*10 -3 mg/L. Moermond & Smit (2015) calculated a PNEC for carbamazepine of 0.5 µg/L.
They used an assessment factor of 50 instead of 10 because they did not obtain chronic toxicity data of H. vulgaris, which was the most sensitive species based on their acute ecotoxicity data. In this study, a chronic toxicity value is presented of H. vulgaris, but Moermond & Smit (2015) considered this value as acute.
Gemfibrozil
Toxicity data that was excluded for the PNEC derivation had no population relevant endpoints (e.g. enzyme and decrease of plasma testosterone). For the Anabaena species, two EC50s were available with the same endpoint. However, due to the large difference between the two test durations the lowest value is taken for the PNEC derivation instead of the geometric mean. For the PNEC derivation an assessment factor of 50 was used due to the lack of a chronic toxicity data for fish. This resulted in a PNEC of are 1.56*10 -3 mg/L.
Metformin
To derive a PNEC for metformin, an assessment factor of 10 was be used because there were at least three NOECs available for the basic set of species. The assessment factor is applied to the lowest NOEC, which is 1.00*10 1 mg/l for D. rerio resulting in a PNEC of 1.0 mg/L.
Metoprolol
The only available chronic data was excluded for the PNEC derivation due to the nonpopulation relevant endpoints and the reliability of the values (Moermond & Smit, 2015) .
The data came from the study of Triebskorn et al. (2004) . Due to the lack of useful chronic toxicity data an assessment factor of 1000 is used to calculate the PNEC of 7.59*10 -3 mg/L.
Fluoxetine
The reason for the exclusion of some data points was due to their non-population relevant endpoints (e.g. induction of phagocytosis). It needs to be mentioned that data was used from toxicity tests that examined the effects of different enantiomers of fluoxetine (Stanley et al., 2007) . No chronic toxicity data were available for an algae species, and therefore an assessment factor of 50 was used resulting in a PNEC of 4.24*10 -4 mg/L. 
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